Quinidine Shortage: What Providers and Prescribers Need to Know in 2026

Despite the absence of an active FDA-declared shortage, quinidine remains one of the more challenging medications to reliably source for patients in 2026. For cardiologists, electrophysiologists, and general practitioners managing patients on this Class IA antiarrhythmic, understanding the landscape of availability — and having a clinical action plan — is increasingly important.

Current Quinidine Availability Status (2026)

As of 2026, oral quinidine is not listed on the FDA Drug Shortages Database as an active shortage. However, prescribers should be aware of the following structural availability issues:

All brand-name formulations have been discontinued. Quinaglute, Quinidex, Cardioquin, and Quinora are no longer manufactured. Prescriptions can only be filled with generic quinidine sulfate (200 mg, 300 mg) or quinidine gluconate ER (324 mg).

IV quinidine gluconate is permanently discontinued in the US (since 2019). This directly affects inpatient management of severe P. falciparum malaria and patients requiring parenteral antiarrhythmic therapy where quinidine was the agent of choice.

Limited generic manufacturers mean supply is fragile. A production disruption at any single manufacturer can create regional shortages without triggering an FDA shortage classification.

Pharmacy inventory is inconsistent. Chain pharmacies with automated inventory management often deprioritize low-volume generics like quinidine. Independent and hospital-affiliated pharmacies tend to have better stock.

Patient Populations Most Vulnerable to Quinidine Unavailability

Certain patient populations have limited or no equivalent alternatives to quinidine:

Brugada syndrome: Quinidine's Ito-blocking properties make it the primary oral pharmacotherapy for arrhythmic storm in Brugada syndrome. A 2013 JACC paper noted that quinidine is inaccessible in many countries — a problem now extending to some US regions. For non-medicated patients with Brugada who depend solely on quinidine, ICD placement should be reassessed if the drug becomes indefinitely unavailable.

Idiopathic ventricular fibrillation and short QT syndrome: These rare conditions have few well-studied pharmacological options; quinidine is often the agent with the most supporting data.

Patients with AFib who have failed or cannot tolerate other antiarrhythmics: For this subset, quinidine may represent a last oral option before ablation or device therapy.

Therapeutic Alternatives by Indication

When quinidine is unavailable or contraindicated, the following drug-class substitutions merit consideration — always with individualized clinical judgment:

AFib rhythm control (no structural heart disease): Flecainide (Class IC) or propafenone (Class IC) are first-line alternatives. Both are widely available as generics.

AFib rhythm control (structural heart disease): Amiodarone (Class III) or dofetilide (Class III) are the primary alternatives. Dofetilide requires in-hospital initiation and renal dose adjustment.

Ventricular arrhythmias: Mexiletine (Class IB), amiodarone, or sotalol. Note that sotalol prolongs QT and requires careful monitoring.

Brugada syndrome / short QT syndrome: No well-validated oral alternative exists with the same mechanism. ICD therapy, catheter ablation consultation, and close EP follow-up are recommended if quinidine is indefinitely unavailable.

Clinical Recommendations for Prescribers

Proactively identify patients on quinidine and flag them in your patient management system as requiring pharmacy availability monitoring.

Recommend specific pharmacies that reliably stock quinidine in your region. Independent pharmacies and hospital outpatient pharmacies are often more reliable sources.

Consider 90-day prescriptions through mail-order pharmacies for stable patients, reducing the frequency of refill failures.

Document your rationale for quinidine use in chart notes, particularly for Brugada and rare channelopathies — this supports prior authorization if insurance requires it, and helps justify urgency if supply issues arise.

Direct patients to medfinder for providers — a service that calls pharmacies on the patient's behalf to find which ones can fill a specific prescription. This can save patients time and reduce care gaps.

Additional Resources for Providers

For a detailed guide on how to help your patients locate quinidine and navigate supply gaps, see our provider's guide to helping patients find quinidine. You can also monitor the FDA Drug Shortages Database and ASHP Drug Shortages list for any changes in official shortage status.